Susanna L Cardell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6063960/publications.pdf

Version: 2024-02-01

61 papers	3,823 citations	136950 32 h-index	128289 60 g-index
61 all docs	61 docs citations	61 times ranked	5684 citing authors

#	Article	IF	Citations
1	Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines. Vaccines, 2021, 9, 619.	4.4	6
2	Natural Killer T-Cell Agonist Î±-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. Frontiers in Immunology, 2020, 11, 581301.	4.8	21
3	Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. Clinical Chemistry, 2020, 66, 1228-1237.	3.2	10
4	Structure-Function Implications of the Ability of Monoclonal Antibodies Against Î±-Galactosylceramide-CD1d Complex to Recognize Î²-Mannosylceramide Presentation by CD1d. Frontiers in Immunology, 2019, 10, 2355.	4.8	5
5	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
6	Defining a novel subset of CD1dâ€dependent type II natural killer T cells using natural killer cellâ€associated markers. Scandinavian Journal of Immunology, 2019, 90, e12794.	2.7	7
7	Dissecting Integrin Expression and Function on Memory B Cells in Mice and Humans in Autoimmunity. Frontiers in Immunology, 2019, 10, 534.	4.8	15
8	Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy. Frontiers in Immunology, 2019, 10, 352.	4.8	10
9	Innate and adaptive stimulation of murine diverse NKT cells result in distinct cellular responses. European Journal of Immunology, 2019, 49, 443-453.	2.9	7
10	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive <scp>MS</scp> from relapsingâ€remitting <scp>MS</scp>. Journal of Neurochemistry, 2018, 146, 322-332.	3.9	14
11	Î³Î´ T Cells Contribute to Injury in the Developing Brain. American Journal of Pathology, 2018, 188, 757-767.	3.8	44
12	Type II NKT Cells: An Elusive Population With Immunoregulatory Properties. Frontiers in Immunology, 2018, 9, 1969.	4.8	75
13	The Yin and Yang of Invariant Natural Killer T Cells in Tumor Immunityâ€"Suppression of Tumor Immunity in the Intestine. Frontiers in Immunology, 2018, 8, 1945.	4.8	21
14	High Interferon-Î³ Uniquely in VÎ´1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 260.	4.8	19
15	A New Mouse Model That Spontaneously Develops Chronic Liver Inflammation and Fibrosis. PLoS ONE, 2016, 11, e0159850.	2.5	11
16	Altered expression of Butyrophilin (BTN) and BTNâ€like (BTNL) genes in intestinal inflammation and colon cancer. Immunity, Inflammation and Disease, 2016, 4, 191-200.	2.7	65
17	The Gut Microbiota Reduces Colonization of the Mesenteric Lymph Nodes and IL-12-Independent IFN-Î³ Production During Salmonella Infection. Frontiers in Cellular and Infection Microbiology, 2015, 5, 93.	3.9	15
18	Absence of surrogate light chain results in spontaneous autoreactive germinal centres expanding VH81X-expressing B cells. Nature Communications, 2015, 6, 7077.	12.8	16

#	Article	IF	Citations
19	The adaptor protein SAP regulates type II NKTâ€cell development, cytokine production, and cytotoxicity against lymphoma. European Journal of Immunology, 2014, 44, 3646-3657.	2.9	11
20	Administration of Sulfatide to Ameliorate Type <scp>I</scp> Diabetes in Nonâ€Obese Diabetic Mice. Scandinavian Journal of Immunology, 2014, 79, 260-266.	2.7	10
21	The immune response after hypoxia-ischemia in a mouse model of preterm brain injury. Journal of Neuroinflammation, 2014, 11, 153.	7.2	63
22	Extracellular matrix of secondary lymphoid organs impacts on B-cell fate and survival. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2915-24.	7.1	77
23	The Peri-islet Basement Membrane, a Barrier to Infiltrating Leukocytes in Type 1 Diabetes in Mouse and Human. Diabetes, 2013, 62, 531-542.	0.6	130
24	Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1827-1832.	7.1	129
25	Sulfatide Attenuates Experimental Staphylococcus aureus Sepsis through a CD1d-Dependent Pathway. Infection and Immunity, 2013, 81, 1114-1120.	2.2	38
26	Zinc Finger Protein 148 Is Dispensable for Primitive and Definitive Hematopoiesis in Mice. PLoS ONE, 2013, 8, e70022.	2.5	5
27	CD4+ Type II NKT Cells Mediate ICOS and Programmed Death-1â€“Dependent Regulation of Type 1 Diabetes. Journal of Immunology, 2012, 188, 3138-3149.	0.8	55
28	Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nature Immunology, 2012, 13, 857-863.	14.5	106
29	Identification of novel glycolipid ligands activating a sulfatideâ€reactive, CD1dâ€restricted, type II natural killer T lymphocyte. European Journal of Immunology, 2012, 42, 2851-2860.	2.9	55
30	Dysregulation of CD1d-Restricted Type II Natural Killer T Cells Leads to Spontaneous Development of Colitis in Mice. Gastroenterology, 2012, 142, 326-334.e2.	1.3	65
31	CD1d Expression in Paneth Cells and Rat Exocrine Pancreas Revealed by Novel Monoclonal Antibodies Which Differentially Affect NKT Cell Activation. PLoS ONE, 2010, 5, e13089.	2.5	15
32	Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. Journal of Experimental Medicine, 2010, 207, 943-952.	8.5	85
33	B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells. PLoS ONE, 2010, 5, e10800.	2.5	24
34	Multiple tissueâ€specific isoforms of sulfatide activate CD1dâ€restricted type II NKT cells. European Journal of Immunology, 2009, 39, 1726-1735.	2.9	96
35	Type II natural killer T cells: a new target for immunomodulation?. Expert Review of Clinical Immunology, 2008, 4, 615-627.	3.0	8
36	Molecular profiling reveals distinct functional attributes of CD1d-restricted natural killer (NK) T cell subsets. Molecular Immunology, 2008, 45, 2607-2620.	2.2	34

#	Article	IF	Citations
37	The extracellular matrix of the spleen as a potential organizer of immune cell compartments. Seminars in Immunology, 2008, 20, 4-13.	5.6	81
38	Severe Defect in Thymic Development in an Insertional Mutant Mouse Model. Journal of Immunology, 2007, 178, 5018-5027.	0.8	10
39	Involvement of the CD1dâ€“Natural Killer T Cell Pathway in Neointima Formation After Vascular Injury. Circulation Research, 2007, 101, e83-9.	4.5	20
40	Reduced neointima formation after vascular injury in CD1 deficient mice. Vascular Pharmacology, 2006, 45, 191.	2.1	0
41	The Complementarity Determining Region 2 of BV8S2 (Vî²8.2) Contributes to Antigen Recognition by Rat Invariant NKT Cell TCR. Journal of Immunology, 2006, 176, 7447-7455.	0.8	34
42	Natural killer T-cell populations in C57BL/6 and NK1.1 congenic BALB.NK mice-a novel thymic subset defined in BALB.NK mice. Immunology, 2005, 114, 336-345.	4.4	16
43	The role of CD1d-restricted NK T lymphocytes in the immune response to oral infection withSalmonella typhimurium. European Journal of Immunology, 2005, 35, 2100-2109.	2.9	62
44	The Enlarged Population of Marginal Zone/CD1dhigh B Lymphocytes in Nonobese Diabetic Mice Maps to Diabetes Susceptibility Region Idd11. Journal of Immunology, 2005, 174, 4821-4827.	0.8	55
45	Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide. Journal of Experimental Medicine, 2004, 199, 947-957.	8.5	369
46	Prevention of Diabetes in Nonobese Diabetic Mice Mediated by CD1d-Restricted Nonclassical NKT Cells. Journal of Immunology, 2004, 173, 3112-3118.	0.8	98
47	Surface receptors identify mouse NK1.1+ Tâ€„cell subsets distinguished by function and Tâ€„cell receptor type. European Journal of Immunology, 2004, 34, 56-65.	2.9	41
48	Amino-terminal anchored surface display in insect cells and budded baculovirus using the amino-terminal end of neuraminidase. Journal of Biotechnology, 2004, 114, 21-30.	3.8	28
49	MHC-dependent and -independent modulation of endogenous Ly49 receptors on NK1.1+ T lymphocytes directed by T-cell receptor type. Immunology, 2003, 110, 313-321.	4.4	18
50	Differential regulation of Ly49 expression on CD4+ and CD4-CD8- (double negative) NK1.1+ T cells. European Journal of Immunology, 2000, 30, 2488-2496.	2.9	32
51	CD1d-Specific NK1.1+ T Cells with a Transgenic Variant TCR. Journal of Immunology, 2000, 165, 168-174.	0.8	74
52	Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions. Seminars in Immunology, 2000, 12, 551-560.	5.6	43
53	Murine CD1d-Restricted T Cell Recognition of Cellular Lipids. Immunity, 2000, 12, 211-221.	14.3	445
54	CD1high B cells: a population of mixed origin. European Journal of Immunology, 1999, 29, 3285-3294.	2.9	77

#	Article	IF	Citations
55	CD1high B cells: a population of mixed origin. European Journal of Immunology, 1999, 29, 3285-3294.	2.9	1
56	Manipulation of the superantigen-induced lymphokine response. Selective induction of interleukin-10 or interferon-Î³ synthesis in small resting CD4+ T cells. European Journal of Immunology, 1993, 23, 523-529.	2.9	25
57	The Immune System of Mice Lacking Conventional MHC Class II Molecules. Advances in Immunology, 1993, 55, 423-440.	2.2	38
58	Differential regulation of lymphokine production in mitogen-stimulated murine spleen cells. European Journal of Immunology, 1991, 21, 1887-1892.	2.9	9
59	Helper interleukins are produced by both CD4 and CD8 splenic T cells after mitogen stimulation. European Journal of Immunology, 1991, 21, 2495-2500.	2.9	34
60	Interleukin 2, 4 and 5 are sequentially produced in mitogen-stimulated murine spleen cell cultures. European Journal of Immunology, 1990, 20, 389-395.	2.9	38
61	Improved preparation of the integral membrane proteins of human red cells, with special reference to the glucose transporter. Biochimica Et Biophysica Acta - Biomembranes, 1986, 855, 345-356.	2.6	42